Phase-2 studies of the vaccine named BNT122, developed by BioNTech with mRNA technology, have started. This vaccine, developed for the treatment of colon cancer, seems to be able to make the second deadliest type of cancer lose its importance, or rather cease to be ‘deadly’.
A hope for the whole world with the mRNA-based vaccine developed in the coronavirus epidemic. BioNTechmade a remarkable announcement. In the statements made by the company, it was stated that a new vaccine was produced with the mRNA technique. This vaccine, named BNT122, seems to be a hope for colon cancer if it can be approved.
According to the statements made by the company BNT122 Phase-2 studies of the vaccine have started. In studies carried out with the participation of around 200 patients in the USA, Germany, Belgium and Spain, cancer-causing of tumors It is focused on understanding whether it reappears in the body and whether it is related to the effectiveness of the vaccine.
Vaccine may not be limited to colon cancer
BioNTech believes that colon cancer is both very common and second deadliest type of cancer He explained that new treatment methods are needed due to the fact that the BNT122 vaccine is a result of this. If the studies are successful and the vaccine is put into use, it will be possible to reduce the deaths due to colon cancer. preventable looks like.
RELATED NEWS
Pfizer Withdraws Smoking Cessation Drug Because It ‘Causes Cancer’
Although BioNTech’s studies have come to the fore with colon cancer, the vaccine developed solution to more cancer types probable too. Because the company is trying to use the same vaccine for other types of cancer. At the end of the studies, a few years later, in the cancer gene the possibility of our blood being drawn may have disappeared completely.
Source :
https://www.aa.com.tr/tr/saglik/biontech-kolon-kanseri-asisini-faz-2-denemelerin-basladi/2379930